CAMBRIDGE, and MACCLESFIELD, UK — December 3, 2020 — The consortium behind the DeepADMET project set up to advance artificial intelligence (AI) technologies for drug discovery, today announced the successful conclusion of this project which was funded by Innovate UK, the UK’s innovation agency. Optibrium Limited—a developer of software for drug discovery, Intellegens Limited—an AI company, and Medicines Discovery Catapult (MDC)—the UK’s catapult center for medicine research and innovation, partnered to harness the power of AI for drug discovery and develop a next-generation software platform supporting the design of new drug candidates. In collaboration with global pharma and biotech companies, the consortium demonstrated the ability of its new AI platform, Cerella™, to identify compounds with improved ‘on target’ properties more efficiently and was proven to reduce costs and shorten discovery cycle times.
The successful project culminated in the release of Cerella, which leverages Intellegens’ unique Alchemite™ deep learning algorithm , custom-tailored by the joint research team to the specificities of drug discovery data. The platform complements current drug discovery processes, improving efficiency and productivity by extracting additional value from drug discovery data to make more accurate predictions of compounds’ activity and absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties. Based on these predictions, it prioritizes experimental efforts and increases confidence in decisions. [2,3] Cerella combines on-premises deployment with cloud computing, providing both data security and scalability, and by connecting directly with a corporate data repository, it automatically updates predictions using the latest data.
Karen Spink, innovation lead—precision medicine at Innovate UK: “The digital and AI revolution will lead to faster and smarter ways of discovering and developing safe and effective drugs. Applying the diverse expertise within the DeepADMET project consortium, unique solutions to the predictive modelling of drug candidates have been delivered through the Cerella platform. Advancements in this exciting area of innovation will ultimately deliver better-targeted medicines with an optimized safety profile more quickly to the patient.”
Matthew Segall, CEO at Optibrium: “We appreciate the support received from Innovate UK, enabling us to advance the development of our AI platform, Cerella. As proven by several case studies, Cerella fills a critical need in modern drug discovery, with collaborators’ research and development teams eager to exploit its capacity to accelerate their discovery of novel breakthrough treatments. We are grateful for Innovate UK’s initiatives that enable collaborations like ours, and will continue to work with Intellegens and MDC to further the UK’s role in drug discovery.”
Ben Pellegrini, CEO at Intellegens: “This project represents a significant step forward for Intellegens. Through this collaborative project, we have validated the underlying science with some of the biggest pharma companies in the world, and more importantly, wrapped it up in a robust, deployable platform. We look forward to building on this technology and continuing our collaboration with Optibrium.”
John P. Overington, chief informatics officer at Medicines Discovery Catapult: “The power that comes from discovering and preparing the data needed for medicines research cannot be overstated. This project is unequivocal in its demonstration of how quality data can refine, direct and expedite drug discovery, resulting in faster and flexible routes to the clinic while minimizing overall project costs.”
“It has been an extremely rewarding venture working with Optibrium and Intellegens during this project; a collaboration which will enable a more streamlined and efficient approach to drug discovery and be able to see future applications in other key business areas.”